The acquisition will add AveXis top drug to its repertoire of drugs, which has a significant market in the U.S. for spinal muscular atrophy. On Monday, Switzerland-based healthcare giant Novartis announced its $8.7 billion deal to acquire AveXis; Novartis will… Read More ›